Valvular Aortic valve articles

Debemos tener en cuenta a la isquemia crítica de MM II en el TAVI

Is TAVR at Hospitals Without Backup Cardiovascular Surgery Feasible?

Is TAVR at Hospitals Without Backup Cardiovascular Surgery Feasible?

Patients undergoing transcatheter aortic valve replacement (TAVR) at hospitals without cardiovascular surgery available are at significantly higher risk. That in itself is a call for attention; however, a propensity-matched analysis shows that the short- and long-term mortality rates are similar among patients treated at hospitals with and without cardiovascular surgery backup. This debate emerged a

acceso

Aortic Stenosis and Dialysis: Is TAVR the Strategy of Choice?

Courtesy of Dr. Carlos Fava. TAVR has been shown beneficial in high and moderate risk patients, but there is a group of patients that require dialysis on account of kidney deterioration.  This comorbidity is due to bad cardiovascular evolution associated to diabetes, bleeding and thromboembolic events.   For some time, we have been using an

La enfermedad coronaria funciona como un predictor a 30 días en el TAVI

CoreValve US Pivotal High Risk Trial: at 5 years, similar results

Courtesy of Dr. Carlos Fava. We are well aware of transcatheter aortic valve replacement’s (TAVR) effect in high-risk or inoperable patients at 5 years, even more after the PARTNER 1 trial. Yet, the outcomes of another relevant randomized study remained pending: el CoreValve US Pivotal High-Risk Trial. The CoreValve US Pivotal High-Risk Trial looked at the

¿Es durable el TAVI a más de 5 años?

Surprises in the Physiopathology of Critical Ischemia

Luminal thrombotic occlusions associated with non-significant atherosclerosis are commonly observed in patients with critical lower limb ischemia, which suggests the possibility of thromboembolic disease as a great contributor to ischemia. This was particularly verifiable in infrapopliteal vessels, thus showing a possible mechanism of progression from peripheral vascular disease to critical ischemia, as well as a

TAVI-compressor

Differences in Stroke between TAVR and SAVR in Intermediate Risk Patients

Transcatheter aortic valve replacement (TAVR) is more and more frequent in lower risk populations that had previously been treated with surgical valve replacement (SAVR). A small difference in neurological events could have significant consequences when it comes to deciding a course of action. This study is a sub-analysis of the randomized study SURTAVI (Surgical Replacement

TAVI en bajo riesgo con “cero” mortalidad y “cero” stroke

TAVR in Low-Risk Patients with “Zero” Mortality and “Zero” Stroke

Transcatheter aortic valve replacement (TAVR) is now the standard of care for patients with symptomatic severe aortic stenosis who are at extreme, high, or intermediate risk for surgery. This multicenter, prospective study (Feasibility of Transcatheter Aortic Valve Replacement in Low-Risk Patients With Symptomatic, Severe Aortic Stenosis) included low-risk patients and was approved by the United

Cortar las valvas, una medida extrema para evitar la oclusión coronaria post TAVI

How to predict post TAVR quality of life in “real world” patients

Despite the benefit for most patients, a small number of patients still show poor outcomes after transcatheter aortic valve implantation (TAVR). This work was able to recalibrate a previously developed risk model to predict post TAVR quality of life and provide us with a potential tool to properly estimate the chances of good recovery, or

¿Qué usar para medir funcionalmente una lesión coronaria en el contexto de estenosis aórtica severa?

What Should We Use for the Functional Assessment of Coronary Lesions in Severe Aortic Stenosis?

This systematic analysis measured intracoronary pressure in different phases of the cardiac cycle and flow velocity in patients with severe aortic stenosis and coronary artery disease, who were scheduled for transcatheter aortic valve replacement (TAVR). The aim was to determine the impact of aortic stenosis on: 1) flow, at different phases; 2) hyperemic coronary flow;

COMPASS: un nuevo lugar para el rivaroxaban en cardiopatía isquémica crónica

Galileo: Rivaroxaban After TAVR Stopped Due to Early Event Rates

Patients undergoing transcatheter aortic valve replacement (TAVR) randomized to rivaroxaban in the GALILEO trial experienced higher risk of all-cause death, thromboembolic events, and bleeding compared with patients who received antiplatelet therapy. The GALILEO trial was halted after an early peek of events at the data from the rivaroxaban (Xarelto; Bayer/Janssen) arm. These events included higher

Immediate Electrocardiography After TAVI, the Simplest Way to Predict Conduction Disorders

Taking into account a simple 12-lead electrocardiography performed immediately after transcatheter aortic valve implantation (TAVI), removing the temporary pacemaker immediately is safe in patients without right bundle branch block who are in sinus rhythm with PR interval <240 ms and QRS interval <150 ms. In cases of atrial fibrillation, a QRS interval <140 ms also reassures the decision

¿Es seguro utilizar iFR para diferir lesiones del tronco de la coronaria izquierda?

Ambulatory Continuous Monitoring in Patients with Left Bundle Branch Block After TAVI

The incidence of arrhythmic events up to a year after implantation is high and involves almost half the patients with complete left bundle branch block following the procedure. Significant bradyarrhythmias occur in up to one-fifth of the patients, half of whom ultimately require a pacemaker. These data support the idea of a cardiac monitoring device

Top